The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – Sprue
- Case Report
76-year-old patient with pustular skin rash
- Sponsored Content: Psoriasis
Dauerhafte Erscheinungsfreiheit auch bei betroffenen speziellen Hautarealen
- Antithymocyte globulin in children with T1D
Old medicine, new hope
- Ginkgo biloba
Database of preclinical and clinical studies is becoming increasingly larger
- Digital biomarkers
Continuous monitoring using digital biomarkers in MS care
- Benefits, limits and safety aspects
Phytotherapy for cardiovascular diseases
- Results of the FOREST HCM study